Sleep tends to come easy in winter. The nights are long, it’s cold, so what better place to be than bed? But as the days lengthen, we tend to awaken earlier – curtailing a decent night’s sleep. It’s no trivial matter, as a good night’s sleep is essential to the health of our bodies and […]
By Stephen Adams, Optimum Strategic Communications Few people expected England and Wales’s drugs spending watchdog, the National Institute for Health and Care Excellence (“NICE”), to approve Eli Lilly’s new dementia drug donanemab for use on the NHS last week. At a reputed annual cost of at least £60,000 a year, including the care bill, it […]
Congratulations to our clients AstronauTx and STORM Therapeutics, which were recognised at the inaugural One Nucleus Awards in London in March. AstronauTx scooped the Best Performing Primary R&D Company of the Year Award, while STORM won the One Nucleus Boston Bootcamp competition aimed at getting companies “US-ready”. AstronauTx beat off strong competition to win the […]
Consortium brings together industry, academic, and regulatory experts to advance research and bridge gaps in drug development targeting Alzheimer’s disease Asceneuron to contribute its expertise in neurodegenerative disease to advance biomarkers for drug development in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 26 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to […]
